OncLive TV

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses genomic assays in prostate cancer.

Charles L. Shapiro, MD, professor, College of Medicine, The James, Ohio State University Comprehensive Care Center, discusses the underutilization of preventative drugs for breast cancer.

Marcia S. Brose, MD, PhD, from the University of Pennsylvania, discusses the treatment of anaplastic thyroid cancer (ATC) and the FACT2 study.

Roberto Bordonaro, MD, discusses first-line treatment options for advanced colorectal cancer (CRC).

Gunter von Minckwitz, MD, PhD, Chairman, German Breast Group, Professor of Gynecology, University of Frankfurt, Germany, discusses the rationale behind the phase III PENELOPE trial.

Ayalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the toxicity of imetelstat in patients with myelofibrosis.

Deepak A. Kapoor, MD, former president of the Large Urology Group Practice Association (LUGPA), discusses the successes of and challenges facing LUGPA.

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses extended RAS mutations in colon cancer.

Frederick Alan Rapoport, MD, clinical instructor in the Department of Medicine at NYU Langone Medical Center, describes the mechanism and utility of Samsca (tolvaptan).

Jennifer E. Amengual, MD, discusses the development of novel agents for subtypes of diffuse large b-cell lymphoma.

Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, discusses a study looking at patients' family history, BRCA mutation status, and breast cancer risk.

Ramesh K. Ramanathan, MD, discusses the potential of identifying actionable targets in appendiceal cancers.

Bryan A. Mehlhaff, MD, from the Oregon Urology Institute, discusses prostate cancer screening guidelines.

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, describes the design of a phase II trial looking at the single-agent activity of the proteasome inhibitor MLN9708 for the treatment of patients with multiple myeloma.

Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, discusses the potential of immunotherapy for the treatment of patients with lung cancer.

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, gives an update on a four-year follow-up analysis of the NeoALTTO trial.

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, gives an overview of new therapies for pancreatic cancer.

Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses some of the challenges of treating patients with lung cancer.

William J. Gradishar, MD, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses the treatment of early stage breast cancer with endocrine therapy and considerations following resistance.

Juliet N. Barker, MBSS, director, Cord Blood Transplantation Program, Memorial Sloan-Kettering Cancer Center, discusses using double-unit cord blood transplantation with a haplo-identical donor in patients with hematologic malignancies.

Robert Laszewski, President, Health Policy and Strategy Associates, LLC, discusses the effects of the Affordable Care Act (ACA) on urology practices.

Alice T. Shaw, MD, PhD, discusses how crizotinib has changed patient care over the last few years.

Martin S. Tallman, MD, Chief, Leukemia Service, Memorial Sloan-Kettering Cancer Center, discusses the treatment of hairy cell leukemia (HCL) with a BRAF inhibitor.

Ruth M. O'Regan, MD, director of Translational Breast Cancer Research, professor, hematology and oncology, medical oncology, Winship Cancer Institute, Emory University, discusses resistance to endocrine therapy in patients with metastatic, hormone receptor-positive breast cancer.

Juan A. Reyna, MD, President, LUGPA, discusses in-office ancillary services among LUGPA members.

Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses using Doxil to treat ovarian cancer.

Vicki Keedy, MD, assistant professor of medicine, clinical director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses a trial looking at quantitative imaging biomarkers of treatment response in osteosarcoma.

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses the phenomenon of pseudoprogression in patients with lung cancer after they receive immunotherapy treatment.

Jerry Lanchbury, PhD, Chief Scientific Officer, Myriad Genetics, Inc., describes the HRD (homologous recombination deficiency) test.

Raoul Concepcion, MD, director of clinical research, urologic surgeon, Urology Associates, PC, in Nashville, Tennessee discusses some of the challenges that independent and community urologists face.